Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Rhea-AI Summary

Crescita Therapeutics Inc. held its 2022 Annual General and Special Meeting in Laval, Quebec, where significant shareholder decisions took place. The election of directors showed strong support, with Daniel N. Chicoine receiving 96.9% of votes for his position. Ernst & Young LLP was reappointed as the external auditor with 99.7% approval. Additionally, Crescita's Shareholder Rights Plan was approved, garnering 97.5% of votes. The meeting emphasized the company's commitment to growth and innovation in the dermatology sector.

Positive

• Strong support for director nominees, with Daniel N. Chicoine receiving 96.9% approval.
• Ernst & Young LLP reappointed as external auditors with 99.7% support.
• Shareholder Rights Plan approved with 97.5% of votes.

Negative

• None.

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2022 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec. The detailed results of the votes received by proxy are as follows:

Election of Directors

Director Nominees		NUMBER OF SHARES				PERCENTAGE OF VOTES CAST
		FOR		WITHHELD		FOR		WITHHELD
Daniel N. Chicoine		4,616,653		148,815		96.9%		3.1%
David A. Copeland		4,378,536		386,932		91.9%		8.1%
Anthony E. Dobranowski		4,363,268		402,200		91.6%		8.4%
John C. London		4,375,612		389,856		91.8%		8.2%
Thomas Schlader		4,692,345		73,123		98.5%		1.5%
Deborah Shannon-Trudeau		4,705,132		60,336		98.7%		1.3%

Appointment of External Auditors

Outcome		NUMBER OF SHARES				PERCENTAGE OF VOTES CAST
		FOR		WITHHELD		FOR		WITHHELD
Ernst & Young LLP reappointed		5,442,357		15,130		99.7%		0.3%

Approval of the Continuation of Crescita’s Shareholder Rights Plan

Outcome		NUMBER OF SHARES				PERCENTAGE OF VOTES CAST
		FOR		AGAINST		FOR		AGAINST
Shareholder Rights Plan approved		4,648,487		116,981		97.5%		2.5%

About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220512006074/en/

Crescita Therapeutics

Investor Relations

Linda Kisa, CPA, CA

Email: lkisa@crescitatx.com

Source: Crescita Therapeutics

Source: Crescita Therapeutics

FAQ

What were the voting results for Crescita Therapeutics at the 2022 Annual General Meeting?

Crescita Therapeutics reported strong voting results, with significant support for directors and measures, including 96.9% for Daniel N. Chicoine and 99.7% for Ernst & Young LLP as auditors.

What is the outcome of the Shareholder Rights Plan for Crescita Therapeutics?

The Shareholder Rights Plan for Crescita Therapeutics was approved with 97.5% of votes in favor at the 2022 Annual General Meeting.

Who were the directors elected at Crescita Therapeutics' 2022 Annual Meeting?

Directors elected included Daniel N. Chicoine, David A. Copeland, Anthony E. Dobranowski, John C. London, Thomas Schlader, and Deborah Shannon-Trudeau, all receiving strong support from shareholders.

When did Crescita Therapeutics hold its Annual General Meeting?

Crescita Therapeutics held its 2022 Annual General and Special Meeting on the specified date at its corporate headquarters in Laval, Quebec.

What company is represented by the stock symbol CRRTF?

CRRTF represents Crescita Therapeutics Inc., a Canadian commercial dermatology company.